Legend Biotech Corporation announced, effective January 20, 2026, its Board of Directors appointed Robin Meng to the Board as a Class III director, with an initial term until Legend Biotech?s 2026 annual general meeting of shareholders. Mr. Meng was appointed to replace Dr. Li Zhu who resigned from the Board on the Effective Date (as described above). Mr. Meng has significant experience in senior leadership, finance, and corporate governance in the life sciences and biotechnology sector.
He is the chairman and an executive Director of GenScript, and has been employed at GenScript in various roles since 2010. Prior to joining GenScript, Mr. Meng served in finance roles at Quay Magnesium, Saint Gobain Grains, and Schering-Plough China. He holds a Bachelor of Engineering from Changsha University of Science and Technology and a Master of Finance from Queen?s University in, Canada.
On January 20, 2026, Dr. Li Zhu and Yau Wai Man Philip resigned from the Board, effective as of the Effective Date. Each resignation was not the result of any dispute or disagreement with Legend Biotech on any matter relating to its operations, policies (including accounting or financial policies) or practices. Following Mr. Yau?s resignation, Tomas Heyman was appointed as the chair of Audit Committee of the Board, effective as of the Effective Date.
